These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Tonstad S Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916 [TBL] [Abstract][Full Text] [Related]
47. Effect of rimonabant on weight and cardiometabolic risk factors. Gadde KM JAMA; 2006 Aug; 296(6):649-50; author reply 650-1. PubMed ID: 16896103 [No Abstract] [Full Text] [Related]
48. [Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects]. Wettermark B; Raaschou P; Forslund T; Hjemdahl P Lakartidningen; 2007 Dec; 104(51-52):3879-81. PubMed ID: 18232530 [No Abstract] [Full Text] [Related]
49. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. Scheen AJ J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513 [TBL] [Abstract][Full Text] [Related]
50. Panel advises against rimonabant approval. Traynor K Am J Health Syst Pharm; 2007 Jul; 64(14):1460-1. PubMed ID: 17617490 [No Abstract] [Full Text] [Related]
51. Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches. Cervino C; Pasquali R; Pagotto U Mini Rev Med Chem; 2007 Jan; 7(1):21-30. PubMed ID: 17266634 [TBL] [Abstract][Full Text] [Related]
52. Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics. Cardiovasc J Afr; 2008; 19(5):282-3. PubMed ID: 18997994 [No Abstract] [Full Text] [Related]
53. The endocannabinoid system as a novel approach for managing obesity. Lillo JL J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530 [TBL] [Abstract][Full Text] [Related]
54. Rimonabant. SR 141716, SR 141716a. Drugs R D; 2002; 3(1):65-6. PubMed ID: 11881536 [No Abstract] [Full Text] [Related]
55. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Hollander P Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341 [TBL] [Abstract][Full Text] [Related]
56. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]. Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542 [TBL] [Abstract][Full Text] [Related]
57. Pharmacotherapy for obesity--promise and uncertainty. Yanovski SZ N Engl J Med; 2005 Nov; 353(20):2187-9. PubMed ID: 16291989 [No Abstract] [Full Text] [Related]
58. [The role of the cannabinoid system in the pathogenesis and treatment of alcohol dependence]. Pietrzak B; Dunaj A; Piątkowska K Postepy Hig Med Dosw (Online); 2011 Sep; 65():606-15. PubMed ID: 21934185 [TBL] [Abstract][Full Text] [Related]
59. Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction. Gadde KM Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):549-56. PubMed ID: 16503875 [TBL] [Abstract][Full Text] [Related]
60. The hope and fear of rimonabant. Rumsfeld JS; Nallamothu BK JAMA; 2008 Apr; 299(13):1601-2. PubMed ID: 18387935 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]